Welcome to our dedicated page for BiondVax Pharmaceuticals Ltd. news (Ticker: bvxv), a resource for investors and traders seeking the latest updates and insights on BiondVax Pharmaceuticals Ltd. stock.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company pioneering innovative solutions in the realm of inflammation and immunology (I&I). With a robust pipeline of nanosized VHH antibodies known as NanoAbs, BiondVax is targeting diseases with significant unmet medical needs. The company has made notable strides, particularly with its leading product, an intradermal NanoAb targeting IL-17 for treating mild to moderate plaque psoriasis. This product has shown promising results in preclinical ex-vivo trials and is gearing up for human clinical trials in 2025.
BiondVax operates two main business units. The first focuses on the in-house development of biological therapeutic products, leveraging its NanoAb technology licensed from the Max Planck Society and the University Medical Center Göttingen, Germany. The second unit, Scinai Bioservices, is a boutique Contract Development and Manufacturing Organization (CDMO) that offers end-to-end services ranging from drug development to GMP manufacturing. Launched in Q3 2023, Scinai Bioservices has already secured contracts with several biotechnology companies and aims to support small biotech firms in bringing their products to market efficiently.
The company recently welcomed Liat Halpert as Head of Business Development and Sales. Halpert, with her extensive experience from Novartis, is expected to expand Scinai’s CDMO business, particularly targeting European and U.S.-based biotech companies. This strategic move is anticipated to significantly boost BiondVax's revenue and establish it as a key partner for small biotechnology firms.
In recent news, BiondVax announced successful preclinical results of its IL-17 targeting NanoAb for psoriasis treatment. Additionally, its NanoAbs for COVID-19 have shown efficacy in preclinical trials, demonstrating potential in preventing and treating viral respiratory diseases through inhalation, a convenient administration route.
BiondVax's financial stability and strategic partnerships position it well for future growth. The company continues to seek collaborative opportunities with mid and large-cap pharmaceutical companies to advance its NanoAb therapies through clinical trials and towards commercialization.
For the latest updates and detailed information, visit BiondVax’s official website at www.biondvax.com.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) completed a $9.8 million underwritten public offering of American Depositary Shares (ADSs). Aegis Capital Corp. served as the sole bookrunner for the offering. BiondVax focuses on developing innovative treatments for infectious diseases, holding extensive clinical trial experience, including a significant Phase 3 trial involving 12,400 participants. The funds raised are expected to enhance BiondVax's product pipeline, particularly its nanosized antibody (NanoAb) offerings, and support ongoing business development initiatives.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced the closure of a public offering of 4,144,068 American Depositary Shares (ADSs) at $2.36 each, raising approximately $9.8 million in gross proceeds. The funds will support the company's nanosized antibody (NanoAb) development program in collaboration with the Max Planck Institute. CEO Amir Reichman highlighted the significance of this funding for advancing innovative therapies. The offering was conducted under a shelf registration statement with the SEC, and Aegis Capital Corp. served as the sole book-running manager.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced the approval of all resolutions at its Annual General Meeting, including the election of Jay Green to the Board of Directors. Green, who has extensive experience in finance and operations within the vaccine sector, previously served as CFO of GlaxoSmithKline's global vaccines business. His addition is seen as a strategic move to enhance the company's R&D efforts, particularly around their promising nanosized antibody (NanoAb) program. Meanwhile, Isaac Devash has retired from the board after significant contributions.
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) announced a public offering of 3,813,560 American Depositary Shares (ADSs) priced at $2.36 each, aiming for gross proceeds of approximately $9.0 million. The funds will advance its nanosized antibody development program and support general corporate purposes. Closing is expected on December 29, 2021, with a 45-day option for underwriters to purchase additional ADSs, potentially raising proceeds to $9.8 million. Aegis Capital Corp. is the sole book-running manager, with the offering under a shelf registration statement.
BiondVax Pharmaceuticals (Nasdaq: BVXV) announced an underwritten public offering of its American Depositary Shares (ADSs) on December 23, 2021. The company signed agreements with the Max Planck Society and University Medical Center Göttingen to develop nanosized antibodies (NanoAbs) aimed at neutralizing all COVID-19 variants, including Delta and Omicron. Proceeds from the offering will advance the NanoAbs program and cover general corporate purposes. Aegis Capital Corp. is the book-running manager for the offering, which is subject to market conditions.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced strategic agreements with the Max Planck Society and University Medical Center Göttingen to develop innovative COVID-19 nanosized antibodies (NanoAbs). These NanoAbs, exhibiting superior affinity and stability, could neutralize SARS-COV-2 at lower concentrations than current therapies. The collaboration aims to also address other major diseases, including psoriasis and asthma, leveraging the competitive advantages of NanoAbs. Preclinical studies are planned for 2022, with initial clinical results anticipated in 2023.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported its Q3 2021 financial results, reflecting a significant decrease in R&D expenses to NIS 2.0 million ($0.6 million), down from NIS 12.6 million in Q3 2020. Marketing and administrative costs also fell to NIS 6.2 million ($1.9 million), contributing to total operating expenses of NIS 8.2 million ($2.5 million), compared to NIS 20.0 million in the prior year. The company is collaborating with Max Planck Society to develop innovative VHH-antibodies aimed at addressing COVID-19 and other diseases. Cash and equivalents were NIS 34.6 million ($10.7 million) as of September 30, 2021.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced its Annual General Meeting (AGM) scheduled for December 27, 2021, in Tel Aviv, Israel. Key resolutions include the election of Jay Green to the Board of Directors. BiondVax has formed a strategic collaboration with the Max Planck Institute for the development of innovative VHH-antibody therapies, focusing on COVID-19 and other diseases. Preparations for manufacturing these antibodies have commenced at its GMP facility in Jerusalem. The AGM will also cover auditor appointments and the adoption of an updated compensation policy.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced that CEO Amir Reichman will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference on Nov. 15, 2021, at 10:30 am ET. The biopharmaceutical company specializes in developing innovative products for infectious disease prevention and treatment. BiondVax has conducted eight clinical trials, including a Phase 3 trial with 12,400 participants. Investors interested in attending can register at H.C. Wainwright's website.
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced a strategic collaboration with the Max Planck Society and the University Medical Center Göttingen in Germany. The 5-year partnership will allow BiondVax to license novel VHH antibodies, which exhibit enhanced efficacy against COVID-19 variants at lower concentrations than existing treatments. The collaboration aims to address various diseases and will leverage BiondVax's manufacturing capabilities in Jerusalem. Definitive agreements are expected within 90 days, although execution is not guaranteed.
FAQ
What is the market cap of BiondVax Pharmaceuticals Ltd. (bvxv)?
What does BiondVax Pharmaceuticals Ltd. do?
What are NanoAbs?
What recent achievements has BiondVax made?
Who is Liat Halpert?
What services does Scinai Bioservices offer?
When are human clinical trials for the psoriasis NanoAb expected?
What are the potential applications of BiondVax's NanoAbs?
How is BiondVax planning to expand its CDMO business?
What regulatory approvals does BiondVax need?
Where can I find more information about BiondVax Pharmaceuticals Ltd.?
